WallStreetZenWallStreetZen

NASDAQ: CUE
Cue Biopharma Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their CUE stock forecasts and price targets.

Forecast return on equity

Is CUE forecast to generate an efficient return?

Company
14,199.1%
Industry
16.48%
Market
167.41%
CUE's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CUE forecast to generate an efficient return on assets?

Company
1,068.16%
Industry
23.52%
CUE is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CUE earnings per share forecast

What is CUE's earnings per share in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$6.71
Avg 2 year Forecast
-$8.57
Avg 3 year Forecast
$0.24

CUE revenue forecast

What is CUE's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$17.9M-52.52%
Avg 2 year Forecast
$1.0M-97.32%
Avg 3 year Forecast
$55.0M+46.05%
CUE's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CUE revenue growth forecast

How is CUE forecast to perform vs Biotechnology companies and vs the US market?

Company
7.41%
Industry
30.45%
Market
13.33%
CUE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CUE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CUE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CUE$27.67N/AN/A
ACOG$9.21$17.40+88.93%Strong Buy
NKTX$2.79$11.75+321.15%Strong Buy
DTIL$7.37$36.67+397.52%Strong Buy
IPHA$2.11$8.00+279.15%Strong Buy
View Top Biotech Stocks

Cue Biopharma Stock Forecast FAQ

What is CUE's earnings growth forecast for 2026-2028?

(NASDAQ: CUE) Cue Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.25%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.98%.

Cue Biopharma's earnings in 2026 is -$164,108,000.On average, 2 Wall Street analysts forecast CUE's earnings for 2026 to be -$48,718,066, with the lowest CUE earnings forecast at -$47,270,995, and the highest CUE earnings forecast at -$50,647,494. On average, 2 Wall Street analysts forecast CUE's earnings for 2027 to be -$62,291,624, with the lowest CUE earnings forecast at -$60,441,377, and the highest CUE earnings forecast at -$64,758,619.

In 2028, CUE is forecast to generate $1,760,894 in earnings, with the lowest earnings forecast at $1,708,590 and the highest earnings forecast at $1,830,632.

If you're new to stock investing, here's how to buy Cue Biopharma stock.

What is CUE's revenue growth forecast for 2026-2028?

(NASDAQ: CUE) Cue Biopharma's forecast annual revenue growth rate of 7.41% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.45%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.33%.

Cue Biopharma's revenue in 2026 is $37,654,000.On average, 2 Wall Street analysts forecast CUE's revenue for 2026 to be $129,865,929, with the lowest CUE revenue forecast at $126,008,525, and the highest CUE revenue forecast at $135,009,134. On average, 2 Wall Street analysts forecast CUE's revenue for 2027 to be $7,337,058, with the lowest CUE revenue forecast at $7,119,126, and the highest CUE revenue forecast at $7,627,635.

In 2028, CUE is forecast to generate $399,506,448 in revenue, with the lowest revenue forecast at $7,119,126 and the highest revenue forecast at $823,058,106.

What is CUE's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: CUE) forecast ROA is 1,068.16%, which is higher than the forecast US Biotechnology industry average of 23.52%.

What is CUE's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: CUE) Cue Biopharma's current Earnings Per Share (EPS) is -$26.42. On average, analysts forecast that CUE's EPS will be -$6.71 for 2026, with the lowest EPS forecast at -$6.51, and the highest EPS forecast at -$6.97. On average, analysts forecast that CUE's EPS will be -$8.57 for 2027, with the lowest EPS forecast at -$8.32, and the highest EPS forecast at -$8.91. In 2028, CUE's EPS is forecast to hit $0.24 (min: $0.24, max: $0.25).

What is CUE's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: CUE) forecast ROE is 14,199.1%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.